Potassium voltage-gated channel subfamily KQT member 2 (Kv7.2) (Kv7.2)

Potassium voltage-gated channel subfamily KQT member 2 (Kv7.2), encoded by the KCNQ2 gene, is a critical transmembrane protein primarily expressed in the central and peripheral nervous systems (UniProt P48522). It typically assembles with Kv7.3 subunits to form heterotetrameric channels that conduct the M-current, a low-threshold, non-inactivating potassium current that regulates the resting membrane potential and controls the frequency of action potential firing (PubMed: 25237128). Mutations in Kv7.2 are strongly associated with a spectrum of neonatal-onset epilepsies, including Benign Familial Neonatal Convulsions (BFNC) and more severe KCNQ2-related developmental and epileptic encephalopathy (KCNQ2-DEE) (NIH: GeneReviews NBK1522). Beyond epilepsy, Kv7.2 is also implicated in neuropathic pain and tinnitus due to its role in modulating sensory neuron firing (PubMed: 28244310). Pharmacologically, Kv7.2 is a validated therapeutic target; positive allosteric modulators like retigabine (ezogabine) enhance channel opening to dampen neuronal hyperexcitability, providing anticonvulsant and analgesic effects (PubMed: 21482351). Current drug development efforts focus on next-generation Kv7.2/3 openers with improved selectivity and safety profiles to treat refractory epilepsy and neuropathic pain (Xenon Pharmaceuticals, Biohaven). These novel agents aim to avoid the off-target effects and safety issues, such as pigmentation and urinary retention, seen with earlier non-selective Kv7 modulators (PubMed: 24101572).

Other names

KCNQ2Voltage-gated potassium channel subunit Kv7.2Potassium channel subunit alpha Kv7.2BFNCEBF1ENB1KCNA11HNSPC

Drugs targeting Kv7.2 primarily act as positive allosteric modulators (PAMs) that bind to the transmembrane domain to stabilize the open state of the channel, thereby increasing potassium efflux and hyperpolarizing the neuronal membrane (PubMed: 21482351). Conversely, experimental antagonists like XE-991 block the channel pore to inhibit the M-current, which increases neuronal excitability (PubMed: 10658631).